Adaptive Biotechnologies (NASDAQ:ADPT) Price Target Raised to $22.00

Adaptive Biotechnologies (NASDAQ:ADPT) had its price objective raised by Morgan Stanley from $20.00 to $22.00 in a research report report published on Thursday,Benzinga reports. The brokerage currently has an equal weight rating on the stock.

ADPT has been the topic of several other research reports. BTIG Research boosted their target price on shares of Adaptive Biotechnologies from $24.00 to $25.00 and gave the company a “buy” rating in a research note on Thursday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Friday, July 17th. TD Cowen lifted their price target on shares of Adaptive Biotechnologies from $25.00 to $28.00 and gave the company a “buy” rating in a report on Thursday. Guggenheim boosted their price target on shares of Adaptive Biotechnologies from $22.00 to $25.00 and gave the company a “buy” rating in a research report on Thursday. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 6th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $23.33.

Adaptive Biotechnologies Price Performance

Shares of ADPT stock opened at $22.57 on Thursday. The stock’s fifty day simple moving average is $19.43 and its 200 day simple moving average is $16.66. The company has a debt-to-equity ratio of 2.22, a current ratio of 4.79 and a quick ratio of 3.22. The firm has a market cap of $3.61 billion, a price-to-earnings ratio of -55.05 and a beta of 2.07. Adaptive Biotechnologies has a one year low of $9.96 and a one year high of $24.57.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its quarterly earnings results on Tuesday, July 28th. The company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.12). Adaptive Biotechnologies had a negative net margin of 20.73% and a negative return on equity of 36.81%. The company had revenue of $71.55 million during the quarter, compared to the consensus estimate of $65.44 million. During the same quarter last year, the company earned ($0.17) earnings per share. The business’s revenue was up 21.5% on a year-over-year basis. On average, analysts expect that Adaptive Biotechnologies will post -0.43 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Harlan S. Robins sold 492,400 shares of Adaptive Biotechnologies stock in a transaction dated Tuesday, July 21st. The stock was sold at an average price of $21.89, for a total value of $10,778,636.00. Following the completion of the transaction, the insider directly owned 812,058 shares of the company’s stock, valued at $17,775,949.62. The trade was a 37.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Francis Lo sold 44,838 shares of the company’s stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $22.59, for a total transaction of $1,012,890.42. Following the transaction, the insider owned 230,713 shares in the company, valued at approximately $5,211,806.67. This trade represents a 16.27% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 1,305,787 shares of company stock valued at $27,828,563. 5.70% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Adaptive Biotechnologies

A number of large investors have recently modified their holdings of the stock. 1492 Capital Management LLC acquired a new position in shares of Adaptive Biotechnologies during the fourth quarter valued at $1,484,000. Jupiter Asset Management Ltd. boosted its holdings in Adaptive Biotechnologies by 33.8% during the fourth quarter. Jupiter Asset Management Ltd. now owns 362,811 shares of the company’s stock worth $5,892,000 after buying an additional 91,683 shares during the last quarter. Rhenman & Partners Asset Management AB boosted its holdings in Adaptive Biotechnologies by 22.2% during the fourth quarter. Rhenman & Partners Asset Management AB now owns 605,000 shares of the company’s stock worth $9,825,000 after buying an additional 110,000 shares during the last quarter. Westfield Capital Management Co. LP bought a new position in Adaptive Biotechnologies during the fourth quarter worth about $65,942,000. Finally, Jennison Associates LLC grew its position in shares of Adaptive Biotechnologies by 103.9% during the 4th quarter. Jennison Associates LLC now owns 2,674,668 shares of the company’s stock worth $43,437,000 after buying an additional 1,363,181 shares during the period. 99.17% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Adaptive Biotechnologies

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: Adaptive raised its 2026 MRD revenue outlook to $268 million-$278 million and outlined plans to separate the MRD business. Management and analysts view the transaction as a potential way to create a focused, higher-growth “pure-play” company and unlock shareholder value. Adaptive outlines MRD separation plan while raising 2026 MRD revenue guidance
• Positive Sentiment: Second-quarter revenue was approximately $71.6 million, above the roughly $65.4 million consensus estimate and up 21.5% year over year. Zacks also reported an adjusted loss of $0.10 per share, narrower than the expected $0.13 loss and the $0.17 loss in the prior-year quarter. Adaptive Biotechnologies Reports Q2 Loss, Beats Revenue Estimates
• Positive Sentiment: Analysts raised their targets after the results: TD Cowen increased its target to $28 and maintained a Buy rating, while BTIG lifted its target to $25 and also retained a Buy rating. Analyst price-target coverage
• Neutral Sentiment: Zacks noted that ADPT’s 52-week-high performance reflects improving fundamentals, but investors must assess whether revenue growth, margins and the MRD separation can support additional appreciation. Adaptive Biotechnologies Hit a 52 Week High
• Negative Sentiment: Morgan Stanley raised its target only to $22 and kept an Equal Weight rating, implying limited upside at recent trading levels. The company remains unprofitable, and reported GAAP results included a larger-than-consensus quarterly loss, highlighting ongoing execution and profitability risks.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.